• Where To Next With Continuous Processing?

    Today multiple suppliers offer commercial process solutions for continuous cell culture, continuous clarification, continuous chromatography, continuous virus inactivation and continuous filtration and their effectiveness is documented in the technical literature. So, what’s next? We have the tools; the technology is proven and early adopters are active.

  • Securing Bioprocess Film Supply

    Learn how a partnership built on technical expertise and trust is helping to secure the supply of a single-use film built for bioprocessing.

  • UniVessel® Single Use Bioreactor For CHO Fed-Batch Cultures

    The motivation for utilizing single use (SU) bioreactors is the reduced turn-around time and labor required for cleaning and autoclaving traditional glass vessels as well as the associated costs for maintenance and repair.  Sartorius’ 2L UniVessel® SU has an option for an external water jacket system controlled by Sartorius’ BIOSTAT® controllers. In this study, we determined the feasibility of the UniVessel® SU and BIOSTAT® B-DCU II combination by performing detailed comparability studies of cell growth, viability, monoclonal antibody (mAb) productivity and product quality attributes (aggregation, charge variation and glycosylation) using three recombinant CHO cell lines.

  • Extractables Testing On Single-Use Connectors

    Appropriating BPOG testing on single-use connectors to mitigate the risks of E&L, as demonstrated in this article, is crucial to delivering safe and effective drugs.

  • "Validation" Or "Qualification" – What’s The Difference?

    What is the difference between qualification and validation? This question comes up frequently with both internal and external clients. 

More Insights On Enterprise Solutions


  • Meet The API Drug Substance Team At Patheon’s Florence, SC Site

    Watch the video to meet Patheon’s (part of Thermo Fisher Scientific) API drug substance team and get an inside look at their Florence, SC facility.

  • Supporting The Transformation Of The Patient Experience With IASO

    IASO supports stakeholders who are responsible for bringing innovation to market in the form of combination products for oncology.  

  • Bioburden Control Concerns In Continuous Bioprocessing

    The industry is looking for answers about the implementation of continuous bioprocessing. Pall Biotech is here to help you to find them. Watch our video for quick insights into bioburden control strategies in continuous bioprocessing.

  • Standing Out In The Crowded Biopharma CDMO Market

    When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection they are able to communicate what is unique about their offering to the right audience at the right time. 

  • Singota Solutions—Focused on Faster

    This video introduces Singota Solutions, a CDMO focused on getting products to patients faster by being agile, accountable and transparent. A team of industry experts help virtual to large pharma clients reach preclinical and clinical milestones faster with shorter lead times and agile onsite operations. Services in formulation development, finishing and supply chain support Singota’s flagship aseptic filling operations. A gloveless robotic isolator provides highly repeatable and precise filling for high value drug products.

More Enterprise Solutions Multimedia


  • Contract Development And Manufacturing - A CDMO Beyond Measure
    Contract Development And Manufacturing - A CDMO Beyond Measure

    Samsung Biologics is a full integrated CDMO with the largest capacity in the world. We provide development and manufacturing services for biopharmaceutical companies of any size.

  • Ibex™ Develop

    The efficacy and safety of biopharmaceutical products, combined with their ability to address previously untreatable conditions is driving strong demand. Concurrently, to accelerate access to life-changing medicines, the number of breakthrough therapies and fast track designations are increasing, shortening drug development timelines considerably.

  • Ibex™ Dedicate

    As the biopharma industry identifies faster and more efficient ways to deliver drugs to patients, such as break-through and fast track designations for accelerated approval, these progresses create pressure on both large and small drug manufacturers. As development timelines shorten, decisions related to drug commercialization need to be taken earlier, when key results are not yet available. And deciding on the scale and type of facility to build without complete data can create substantial risks with costly consequences.

More Enterprise Solutions